© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > FT-2102 (olutasidenib)
<< Back to February
allosteric mutant-selective IDH1 inhibitor
oral, in clinical development
from SBDD of prior mIDH inhibitor
J. Med. Chem. 2020, 63, 1612-1623
FORMA Therapeutics, Watertown, MA
FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)
Unlock this content with a Premium membership to read it now.